Table 2.
Baseline (BL) and follow‐up (FU) responses to survey outcome measures at three sites
| Type of outcome | Indicators | Examples of items included in scores | Site A | Site B | Site C |
|---|---|---|---|---|---|
| Short term | Ranked score for conflict outcome (0 to 2) | Use of a structured opportunity for deliberation led to successful resolution (2); no structured opportunity but resolved through other means (1); unable to reach agreement (0) |
BL = n/a FU = n/a |
BL = 0 FU = n/a |
BL = n/a FU = n/a |
| Total number of TB clinical trials implemented |
BL = 7 FU = 8 |
BL = 3 FU = 6 |
BL = 0 FU = 0 |
||
| Mutual gain challenges (−4 to 2) | Competition with the public health system for human resources (i.e. qualified staff); infrastructure built for TB trials uses standards relevant for the local health system |
BL = 2 FU = −1 |
BL = −2 FU = −3 |
BL = 0 FU = 0 |
|
| Transparency and integrity challenges (−2 to 1) | Establishing effective communication networks for reporting monitoring of TB cases identified |
BL = 1 FU = −1 |
BL = −2 FU = −1 |
BL = 1 FU = −1 |
|
| Shared knowledge challenges (−2 to 1) | Ensuring local stakeholder understanding of TB disease, treatment and prevention |
BL = 1 FU = −1 |
BL = 1 FU = −1 |
BL = 1 FU=. |
|
| Intermediate & long term | Effective product available as result of most recent trial (Y/N) |
BL = Y FU = Y |
BL = N FU = Y |
n/a | |
| GPP‐TB goal | Access summary score for most recent trial (−5 to 6) | Our site was not able to recruit the target number of participants (−1); the experimental drug tested in the trial is not suitable for use in the local context (−1); the experimental drug tested in the trial is available (1) |
BL = 4 FU = 3 |
BL = −1 FU = 1 |
n/a |
| Social value summary score for most recent trial (−1 to 4) | The trial was closed early (−1); the trial was successfully completed (1); the trial ultimately led to new TB treatment or prevention guidelines (1) |
BL = 4 FU = 4 |
BL = 1 FU = 1 |
n/a | |
| Acceptability summary score for most recent trial (−3 to 2) | The experimental drug tested in the trial is not suitable for use in the local context (−1); the experimental drug tested in the trial is available but many providers refuse to use it (−1); the experimental drug tested in the trial is available and successfully used by providers and patients (1) |
BL = 2 FU = 2 |
BL = 0 FU = 0 |
n/a |
. , missing value.